Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
Hyun Ae JungSehhoon ParkYoon-La ChoiSe-Hoon LeeJin Seok AhnMyung-Ju AhnJong-Mu SunPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This study did not show a survival benefit with the continuation of pembrolizumab with chemotherapy in patients whose NSCLC progressed on second- or third-line PD-1/PD-L1 inhibitors. See related commentary by Tseng and Gainor, p. 2206.
Keyphrases
- phase ii study
- advanced non small cell lung cancer
- locally advanced
- small cell lung cancer
- placebo controlled
- end stage renal disease
- open label
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rectal cancer
- prognostic factors
- squamous cell carcinoma
- clinical trial
- randomized controlled trial
- epidermal growth factor receptor
- combination therapy
- drug induced